Stocktoria
Clene Inc. CLNN
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2018-08-27
Clene Inc. financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $200,000 | $342,000 | $654,000 | $473,000 | $723,000 | $206,000 | — |
| R&D expense | $14.0M | $20.1M | $26.7M | $31.9M | $28.4M | $15.2M | $9.6M |
| Operating income | -$23.1M | -$33.1M | -$40.5M | -$48.4M | -$50.0M | -$20.2M | -$16.3M |
| Interest expense | — | — | $4.6M | $3.3M | $870,000 | $950,000 | $88,000 |
| Income tax | $0 | $0 | $0 | $0 | -$428,000 | $406,000 | — |
| Net income | -$26.2M | -$39.4M | -$49.5M | -$29.9M | -$9.7M | -$19.3M | -$16.2M |
| Operating cash flow | -$18.5M | -$21.3M | -$30.2M | -$39.0M | -$34.6M | -$18.9M | -$13.2M |
| Free cash flow | -$18.6M | -$21.3M | -$30.5M | -$44.2M | -$36.0M | -$19.3M | -$13.5M |
| Cash & equivalents | $5.2M | $12.2M | $28.8M | $18.3M | $50.3M | $59.3M | $8.8M |
| Inventory | $37,000 | $68,000 | $37,000 | $43,000 | $41,000 | $191,000 | $28,000 |
| Total assets | $18.1M | $27.3M | $52.3M | $44.5M | $63.1M | $68.2M | $14.9M |
| Total liabilities | $35.7M | $36.2M | $39.0M | $41.3M | $50.5M | $67.9M | $10.0M |
| Shareholders' equity | -$17.6M | -$8.9M | $13.4M | $3.2M | $12.6M | $341,000 | -$67.8M |
Growth · year-over-year · Revenue CAGR -0.6%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth | -41.5% | -47.7% | +38.3% | -34.6% | +251.0% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.